MedTrace Logo

Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease

NCT02231255 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1216

Last updated 2014-09-17

No results posted yet for this study

Summary

Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for using Sifrol®, equivalent doses at the end of the switch and tolerability of Sifrol® in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions

Conditions

  • Parkinson Disease

Interventions

DRUG

Sifrol®

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2002-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02231255 on ClinicalTrials.gov